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In recent decades, survival from childhood cancer has increased dramatically 
(1) because of improving treatments. In Europe, the five-year relative survival rate 
presently exceeds 75%, with comparable rates reported in the United States (2,3). 
These successes come at the cost of a well-documented increased risk of treatment-
related second cancers in later life. The US Childhood Cancer Survivor Study 
(CCSS) reports a 30-year cumulative incidence of second cancers that exceeds 20% 
in this group of patients (4). Hodgkin’s lymphoma and Ewing sarcoma survivors have 
the greatest risk of developing a second cancer of which breast, brain, bone, thyroid, 
soft tissue, melanoma, and acute myeloid leukemia are most frequently observed 
(5).  
 Despite occurring almost exclusively in females, breast cancer is one of the 
most common subsequent neoplasms in survivors of childhood or adolescent 
cancer. It is particularly prevalent in patients with a primary diagnosis of Hodgkin’s 
lymphoma who received supradiaphragmatic radiotherapy as part of their treatment. 
In a recent UK study of more than 5,000 such women, Swerdlow et al reported a six-
fold increased relative risk of subsequent breast cancer when radiotherapy was the 
sole treatment (6). More dramatic increases were observed when breast cancer risks 
were estimated by age at first radiotherapy treatment; the relative risk of breast 
cancer increased more than 20-fold when radiotherapy was first administered at 
ages 10-14 years, with a peak of almost 50-fold at age 14 years that presumably is 
coincident with breast development (6). Critically, elevated breast cancer risks may 
persist for up to 30 years post-radiotherapy treatment before diminishing (6) and 
consequently, intensive long-term surveillance is warranted for this group of patients. 
At present, besides variables pertaining to treatment, little is known about the 
effects of either genetic or environmental exposures in modifying risk of radiation-
induced second malignancies in childhood cancer survivors. Predicated on the 
hypothesis that common or rare germline variants influence risk of radiation-induced 
breast cancer in this group of individuals, Morton and colleagues (7) performed a 
genome-wide association study (GWAS), which they report in this issue of the 
Journal. They analysed 178 cases and 2,200 controls from the CCSS and 29 cases 
and 574 controls from the St. Jude Lifetime Cohort (SJLIFE), amongst whom a total 
of 131 cases (63%) and 493 controls (18%) received at least 10 Gy radiation 
exposure to the breast during treatment for their first malignancy. Genome-wide 
genotyping and imputation of unobserved genotypes was used to generate a dataset 
of almost 17 million single nucleotide polymorphisms (SNPs) that were represented 
in both cohorts and that were of sufficient quality for statistical analysis. 
SNP rs4342822, localising to 1q41, was statistically significantly associated 
with an almost two-fold raised risk of breast cancer in patients who received at least 
10 Gy radiation to the breast in both CCSS and SJLIFE and surpassed the widely 
applied threshold for genome-wide statistical significance (P ≤ 5x10-08) upon joint 
analysis. The same locus showed no evidence for an association with breast cancer 
risk in individuals who had received lower doses of radiotherapy. Despite the 
relatively small sample size, Morton and colleagues also explored the contributions 
of rare variants upon radiation-induced breast cancer risk and detected independent 
associations of two SNPs, rs74949440 and rs17020562, mapping respectively to 
11q23 and 1q32.3. The associations attributable to these SNPs differed with respect 
to the magnitude of radiation exposure; the former was associated with risk in 
women receiving at least 10 Gy, while the latter was associated with risk only in 
women who received less than 10 Gy. 
Though potentially exciting, a liberal measure of caution is warranted until 
these associations are replicated in independent cohorts; discoveries from small 
GWAS, particularly rare variant associations, often suffer from a high rate of attrition 
as hits that are initially promising subsequently fail to replicate. Indeed, the data from 
Morton et al (7) casts an element of uncertainty upon two previously reported 
associations detected in this setting, at 6q21 and 10q26.13 (8,9). While genetic 
epidemiological studies of sporadic cancer predisposition in the general population 
have identified and robustly validated hundreds of variants that influence of risk of 
most common types of the disease (10), these successes have depended on global 
collaborative efforts to pool vast numbers of samples for analysis (11-13). Clearly 
there are fewer analogous studies with sufficient epidemiological and treatment data 
that also have genetic material for germline analysis, with which to prosecute 
susceptibility to breast cancer in childhood cancer survivors. Nonetheless, this field 
must now move to consolidate available resources in order to expedite validation of 
promising leads. 
Much effort is currently being expended on the development of breast cancer 
predictive models for population-based risk stratification that incorporate germline 
predisposition SNPs. A challenge is that since the breast cancer relative risk effects 
of SNPs are small, they are of little use individually and instead must be combined to 
identify different levels of risk (14). The data reported by Morton et al (7) indicate that 
larger effects might be conferred by a subset of loci involved in mediating risk of 
radiation-induced cancer, suggesting that meaningful risk stratification might be 
attainable with a small number of independent loci. If confirmed, the associations 
presented by Morton et al (7) represent an important step toward delivering upon the 
promise of second cancer risk prediction in childhood cancer survivors.  
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